In recent years, transcatheter aortic valve replacement (TAVR) has become the predominant treatment modality for aortic valve replacement [ ]. New permanent pacemaker implantation (PPMI) occurs within 30 days of 6 %–17 % of TAVR cases, and these rates are generally lower with the use of a balloon-expandable TAVR device versus self-expanding device [ , ].